4D Molecular Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 147
- Market Cap
- $807M
- Introduction
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
Clinical Trials
10
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Single Intravitreal Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Conditions
- Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Interventions
- Biological: 4D-150 IVT (3E10 vg/eye)
- First Posted Date
- 2025-07-15
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- 4D Molecular Therapeutics
- Target Recruit Count
- 400
- Registration Number
- NCT07064759
- Locations
- 🇺🇸
Barnet Dulaney Perkins Eye Center, Sun City, Arizona, United States
🇺🇸Cumberland Valley Retina Consultants, Hagerstown, Maryland, United States
🇺🇸Tennessee Retina, PC, Nashville, Tennessee, United States
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Conditions
- Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Interventions
- Biological: 4D-150 IVT (3E10 vg/eye)
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- 4D Molecular Therapeutics
- Target Recruit Count
- 400
- Registration Number
- NCT06864988
- Locations
- 🇺🇸
Barnet Dulaney Perkins Eye Center, Phoenix, Arizona, United States
🇺🇸Retinal Research Institute, LLC, Scottsdale, Arizona, United States
🇺🇸Retina Partners of Northwest Arkansas, Springdale, Arkansas, United States
4D-150 in Patients With Diabetic Macular Edema
- Conditions
- Diabetic RetinopathyDiabetic Macular Edema
- Interventions
- Biological: 4D-150 IVT
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- 4D Molecular Therapeutics
- Target Recruit Count
- 72
- Registration Number
- NCT05930561
- Locations
- 🇺🇸
Retina Vitreous Associates of Florida, Saint Petersburg, Florida, United States
🇺🇸Retinal Research Institute LLC, Phoenix, Arizona, United States
🇺🇸Retina Consultants of Southern Colorado, Colorado Springs, Colorado, United States
4D-310 in Adults With Fabry Disease and Cardiac Involvement
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- 4D Molecular Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT05629559
- Locations
- 🇦🇺
Royal Melbourne Hospital, Melbourne, Australia
🇦🇺Royal Perth Hospital, Perth, Australia
🇦🇺Westmead Hospital, Westmead, Australia
4D-710 in Adult Patients With Cystic Fibrosis
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- 4D Molecular Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT05248230
- Locations
- 🇺🇸
University of Miami Hospital, Miami, Florida, United States
🇺🇸University of Alabama Child Health Research Unit, Birmingham, Alabama, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
- Prev
- 1
- 2
- Next
News
4D-150 Gene Therapy Shows Promising Results in Diabetic Macular Edema Trial
Phase 1/2 SPECTRA trial of 4D-150 demonstrates consistent efficacy and safety profile in treating diabetic macular edema, with sustained improvements in visual acuity.
ABBV-RGX-314 Gene Therapy Shows Promise in Bilateral Wet AMD
• REGENXBIO's ABBV-RGX-314 gene therapy significantly reduced the need for anti-VEGF injections in patients with bilateral wet AMD. • A Phase 2 substudy demonstrated a 97% decrease in annualized anti-VEGF treatment burden after ABBV-RGX-314 administration in the fellow eye. • 78% of patients were completely free of anti-VEGF injections at 9 months post-treatment, with sustained visual acuity and retinal thickness. • ABBV-RGX-314 was well-tolerated, marking a potential milestone for gene therapy in treating common retinal diseases like wet AMD.
4DMT's 4D-150 Gene Therapy Shows Promise in Wet AMD, Phase 3 Trial Planned
4D Molecular Therapeutics' 4D-150 demonstrated an 89% reduction in the need for standard-of-care injections in wet AMD patients over 52 weeks.
FDA Roundup: TCR T-Cell Therapy Approved, CAR-T REMS Modified, and Clinical Holds Lifted
The FDA granted accelerated approval to Adaptimmune's afami-cel (Tecelra) for unresectable or metastatic synovial sarcoma in patients who have received prior chemotherapy.
4DMT's 4D-310 Shows Promising Cardiac Improvements in Fabry Disease Trial
4D-310 demonstrated clinically meaningful improvements in cardiac contractility, exercise capacity, and quality of life in Fabry disease patients with cardiomyopathy.